In one paragraphArticle in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Kohsuke Kato *Department of Infection Biology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID 0009-0007-3164-9936 Keekushan Okamura *Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Yuki Nakamura *Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Mana IwataCollege of Medical Sciences, School of Medicine and Health Sciences, University of Tsukuba, Tsukuba, Japan.
Mikako HirohamaDepartment of Infection Biology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Yukino OguraDepartment of Infection Biology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Masamitsu KonoDepartment of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.ORCID 0000-0002-7896-4892 Muneki HotomiDepartment of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.ORCID 0000-0003-4705-5319 Tomoko SumitomoDepartment of Oral Microbiology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.ORCID 0000-0003-0653-0339 Atsushi KawaguchiDepartment of Infection Biology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID 0000-0002-5485-1578 Funding
Japan Agency for Medical Research and Development (AMED) JP20fk0108076Japan Agency for Medical Research and Development (AMED) JP22fk0108638Japan Agency for Medical Research and Development (AMED) JP22gm1610008Japan Agency for Medical Research and Development (AMED) JP23wm0325062Japan Agency for Medical Research and Development (AMED) JP24fk0108691Japan Science and Technology Agency JPMJPF2017Japan Society for the Promotion of Science 23K24136Japan Society for the Promotion of Science 25K22548Shionogi Infectious Disease Research Promotion Foundation 2310T00100Takeda Science Foundation (TSF) 2505T00093
6 · The paper itselfAbstract
Secondary bacterial pneumonia is a major complication of influenza A virus (IAV) infection, frequently caused by
Indexed as
Influenza A virusLarynxOrthomyxoviridae InfectionsStreptococcus pneumoniaeAnimalsBiofilmsDisease Models, AnimalFemaleHumansMicePneumococcal InfectionsPneumonia, Pneumococcalanimal modelinfluenza virusin vivo imagingsecondary bacterial infection
Identifiers
PMID42370676
PMCPMC13386995
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390